Skip to main content
SpringerLink
Log in

Rosiglitazon und kardiovaskuläres Risiko

Rosiglitazone and cardiovascular risk

  • Klinische Pharmakologie
  • Published:
Der Kardiologe Aims and scope

Zusammenfassung

Rosiglitazon ist ein orales Antidiabetikum und in Deutschland zur Behandlung des Diabetes mellitus Typ 2 zugelassen ist. In mehreren klinischen Studien konnte gezeigt werden, dass die Therapie von Diabetikern mit Rosiglitazon zu einer anhaltenden Verbesserung der Blutzuckerkontrolle führt. Die Behandlung mit Rosiglitazon ist Bestandteil von Leitlinien nationaler und internationaler Diabetesgesellschaften für die medikamentöse Stufentherapie des Diabetes mellitus Typ 2. Verschiedene Studien weisen allerdings auf ein evtl. erhöhtes kardiovaskuläres Risiko bei der Therapie mit Rosiglitazon hin. Derzeit gilt jedoch die Empfehlung der deutschen Zulassungsbehörde BFARM, dass die neuen Studienergebnisse keine sofortige Beendigung der Behandlung mit Rosiglitazon begründen. Weitere Studien zu dieser Fragestellung stehen an.

Abstract

Rosiglitazone is an oral antidiabetic agent and is licensed in Germany for the treatment of type 2 diabetes mellitus. Several clinical trials have shown that treatment of diabetics with rosiglitazone leads to lasting improvement of blood sugar levels. Treatment with rosiglitazone is an integral part of guidelines issued by national and international diabetes societies for a stepwise approach to drug therapy for type 2 diabetes mellitus. However, various studies suggest the possibility of an increased cardiovascular risk under rosiglitazone therapy. At present though the recommendation of the German BfArM (Federal Agency for Drugs and Medicinal Products which grants authorization) applies that the new study results do not justify immediate discontinuation of rosiglitazone therapy. Further studies addressing this issue are pending.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351(11): 1106–1118

    Article  PubMed  Google Scholar 

  2. Lebovitz HE, Dole JF, Patwardhan R et al. (2001) Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86(1): 280–288

    Article  PubMed  CAS  Google Scholar 

  3. Phillips LS, Grunberger G, Miller E et al. (2001) Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24(2): 308–315

    Article  PubMed  CAS  Google Scholar 

  4. Matthaei S, Haring HU (2007) Behandlung des Diabetes Mellitus Typ 2. Diabetologie 2 [Suppl 2]: S173–S177

  5. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24): 2457–2471

    Article  PubMed  CAS  Google Scholar 

  6. Gerstein HC, Yusuf S, Bosch J et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541): 1096–1105

    Article  PubMed  CAS  Google Scholar 

  7. Kahn SE, Haffner SM, Heise MA et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23): 2427–2443

    Article  PubMed  CAS  Google Scholar 

  8. Home PD, Pocock SJ, Beck-Nielsen H et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 357(1): 28–38

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

  1. Center for Cardiovascular Research (CCR), Institut für Pharmakologie, Charité – Universitätsmedizin Berlin, Hessische Straße 3–4, 10115, Berlin, Deutschland

    U. Kintscher

Authors
  1. U. Kintscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Kintscher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kintscher, U. Rosiglitazon und kardiovaskuläres Risiko. Kardiologe 1, 139–142 (2007). https://doi.org/10.1007/s12181-007-0017-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-007-0017-1

Schlüsselwörter

Keywords

Search

Navigation